Analysis of the XENDOS study (Xenical in the Prevention of Diabetes in Obese Subjects)

Endocrine Practice

Volumn 12, Issue SUPPL. 1, 2006, Pages 31-33

  Sjöström, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PLACEBO; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; LACTONE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CODING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT DURATION; WEIGHT REDUCTION; GLUCOSE INTOLERANCE; REVIEW;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GLUCOSE INTOLERANCE; HUMANS; LACTONES; LIFE STYLE; OBESITY; PLACEBOS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; WEIGHT LOSS;

EID: 33646586687     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.12.s1.31     Document Type: Conference Paper

References (2)

1. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [erratum in Diabetes Care. 2004;27:856]. Diabetes Care. 2004;27:155-161.
2. Torgerson JS, Arlinger K, Käppi M, Sjöström L. Principles for enhanced recruitment of subjects in a large clinical trial: the XENDOS (XENical in the Prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials. 2001;22:515-525.